20,521 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Hsbc Holdings PLC

Posted by George Bondi on Jul 31st, 2026

Hsbc Holdings PLC purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 20,521 shares of the company’s stock, valued at approximately $686,000.

A number of other hedge funds have also recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics during the fourth quarter valued at approximately $26,000. Harbour Investments Inc. lifted its holdings in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Finally, Generali Investments Management Co LLC grew its position in Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares during the period.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the transaction, the insider owned 34,826 shares in the company, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a report on Monday, May 11th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective for the company. Finally, Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Get Our Latest Stock Analysis on STOK

Stoke Therapeutics Stock Up 1.9%

Shares of NASDAQ:STOK opened at $30.04 on Friday. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -10.69 and a beta of 1.17. Stoke Therapeutics, Inc. has a 12-month low of $12.40 and a 12-month high of $40.22. The business’s 50 day moving average is $30.39 and its 200 day moving average is $32.01.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

About Stoke Therapeutics

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.